DE69228814T2 - Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie - Google Patents

Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie

Info

Publication number: DE69228814T2
Authority: DE; Germany
Prior art keywords: vitamin; rats; use according; analogue; administered
Prior art date: 1991-06-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69228814T

Other languages

German (de)

English (en)

Other versions

DE69228814D1 (de

Inventor

Joaquin J. Jimenez

Adel A. Yunis

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

HAIRBIOTECH Inc

Original Assignee

HAIRBIOTECH Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-06-28

Filing date

1992-06-26

Publication date

1999-11-11

1992-06-26 Application filed by HAIRBIOTECH Inc filed Critical HAIRBIOTECH Inc

1999-05-06 Application granted granted Critical

1999-05-06 Publication of DE69228814D1 publication Critical patent/DE69228814D1/de

1999-11-11 Publication of DE69228814T2 publication Critical patent/DE69228814T2/de

2012-06-27 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

201000004384 Alopecia Diseases 0.000 title claims abstract description 79
238000002512 chemotherapy Methods 0.000 title claims description 25
231100000360 alopecia Toxicity 0.000 title abstract description 56
238000000034 method Methods 0.000 title abstract description 19
239000003102 growth factor Substances 0.000 claims abstract description 22
239000000203 mixture Substances 0.000 claims abstract description 21
239000002246 antineoplastic agent Substances 0.000 claims abstract description 13
229940127089 cytotoxic agent Drugs 0.000 claims abstract description 13
239000002207 metabolite Substances 0.000 claims abstract description 12
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 41
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 40
239000011647 vitamin D3 Substances 0.000 claims description 40
229940021056 vitamin d3 Drugs 0.000 claims description 40
235000005282 vitamin D3 Nutrition 0.000 claims description 36
229960005084 calcitriol Drugs 0.000 claims description 32
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 30
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 claims description 28
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 23
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 19
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 19
102000009024 Epidermal Growth Factor Human genes 0.000 claims description 18
101800003838 Epidermal growth factor Proteins 0.000 claims description 18
229940116977 epidermal growth factor Drugs 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 15
241001465754 Metazoa Species 0.000 claims description 14
230000003779 hair growth Effects 0.000 claims description 10
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 9
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 9
230000022131 cell cycle Effects 0.000 claims description 9
229940126864 fibroblast growth factor Drugs 0.000 claims description 8
208000022605 chemotherapy-induced alopecia Diseases 0.000 claims description 7
150000003722 vitamin derivatives Chemical class 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 5
206010068168 androgenetic alopecia Diseases 0.000 claims description 4
239000006210 lotion Substances 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
239000006071 cream Substances 0.000 claims description 2
239000002674 ointment Substances 0.000 claims description 2
230000004936 stimulating effect Effects 0.000 claims 3
150000004347 all-trans-retinol derivatives Chemical class 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000003676 hair loss Effects 0.000 abstract description 18
208000024963 hair loss Diseases 0.000 abstract description 17
229940088594 vitamin Drugs 0.000 abstract description 3
229930003231 vitamin Natural products 0.000 abstract description 3
235000013343 vitamin Nutrition 0.000 abstract description 3
239000011782 vitamin Substances 0.000 abstract description 3
230000002401 inhibitory effect Effects 0.000 abstract 2
239000013543 active substance Substances 0.000 abstract 1
241000700159 Rattus Species 0.000 description 106
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 28
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 27
239000000243 solution Substances 0.000 description 18
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 16
229940009456 adriamycin Drugs 0.000 description 14
229960005420 etoposide Drugs 0.000 description 14
238000007920 subcutaneous administration Methods 0.000 description 13
235000019441 ethanol Nutrition 0.000 description 11
210000003128 head Anatomy 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
239000004322 Butylated hydroxytoluene Substances 0.000 description 9
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 9
101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 9
239000007853 buffer solution Substances 0.000 description 9
235000010354 butylated hydroxytoluene Nutrition 0.000 description 9
229940095259 butylated hydroxytoluene Drugs 0.000 description 9
239000000872 buffer Substances 0.000 description 8
235000019282 butylated hydroxyanisole Nutrition 0.000 description 8
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
230000000699 topical effect Effects 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
230000000694 effects Effects 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
210000004209 hair Anatomy 0.000 description 6
239000004255 Butylated hydroxyanisole Substances 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
229940043253 butylated hydroxyanisole Drugs 0.000 description 5
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 5
229910001220 stainless steel Inorganic materials 0.000 description 5
239000010935 stainless steel Substances 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 4
229930003316 Vitamin D Natural products 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
229960002216 methylparaben Drugs 0.000 description 4
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
210000004761 scalp Anatomy 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
235000019166 vitamin D Nutrition 0.000 description 4
239000011710 vitamin D Substances 0.000 description 4
150000003710 vitamin D derivatives Chemical class 0.000 description 4
229940046008 vitamin d Drugs 0.000 description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
235000020964 calcitriol Nutrition 0.000 description 3
239000011612 calcitriol Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
210000003780 hair follicle Anatomy 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000000344 soap Substances 0.000 description 3
238000012453 sprague-dawley rat model Methods 0.000 description 3
NEJYHHVQXBABIQ-WCTWPDOZSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NEJYHHVQXBABIQ-WCTWPDOZSA-N 0.000 description 2
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
230000009102 absorption Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229960000541 cetyl alcohol Drugs 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
229940124274 edetate disodium Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
229940113124 polysorbate 60 Drugs 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
229960003415 propylparaben Drugs 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
239000001587 sorbitan monostearate Substances 0.000 description 2
235000011076 sorbitan monostearate Nutrition 0.000 description 2
229940035048 sorbitan monostearate Drugs 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
229940100613 topical solution Drugs 0.000 description 2
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 description 1
JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 1
239000003872 25-hydroxy-cholecalciferol Substances 0.000 description 1
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
235000021318 Calcifediol Nutrition 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000018386 EGF Family of Proteins Human genes 0.000 description 1
108010066486 EGF Family of Proteins Proteins 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
101100118555 Mus musculus Egf gene Proteins 0.000 description 1
101100225178 Mus musculus Gfm1 gene Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
-1 Polyoxyethylene stearate Polymers 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607715 Serratia marcescens Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
230000008512 biological response Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000010256 bone deposition Effects 0.000 description 1
JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229940124563 hair growth stimulant Drugs 0.000 description 1
230000003659 hair regrowth Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940057917 medium chain triglycerides Drugs 0.000 description 1
229940042472 mineral oil Drugs 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000003658 preventing hair loss Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229940012831 stearyl alcohol Drugs 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000001913 submandibular gland Anatomy 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940042129 topical gel Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
239000005544 vitamin D3 metabolite Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Birds (AREA)
Molecular Biology (AREA)
Cosmetics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE69228814T 1991-06-28 1992-06-26 Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie Expired - Fee Related DE69228814T2 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US72250091A	1991-06-28	1991-06-28
US78678891A	1991-11-01	1991-11-01
US81041291A	1991-12-20	1991-12-20
PCT/US1992/005241 WO1993000079A1 (en)	1991-06-28	1992-06-26	Method of preventing and treating chemotherapy-induced alopecia

Publications (2)

Publication Number	Publication Date
DE69228814D1 DE69228814D1 (de)	1999-05-06
DE69228814T2 true DE69228814T2 (de)	1999-11-11

Family

ID=27419035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69228814T Expired - Fee Related DE69228814T2 (de)	1991-06-28	1992-06-26	Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie

Country Status (15)

Country	Link
EP (1)	EP0591378B1 (hu)
JP (1)	JPH06509072A (hu)
AT (1)	ATE178206T1 (hu)
AU (1)	AU667675B2 (hu)
CA (1)	CA2112496A1 (hu)
CZ (1)	CZ280874B6 (hu)
DE (1)	DE69228814T2 (hu)
HU (1)	HUT66153A (hu)
IE (1)	IE922088A1 (hu)
IL (1)	IL102344A (hu)
PH (1)	PH31673A (hu)
PT (1)	PT100638B (hu)
SK (1)	SK279673B6 (hu)
TW (1)	TW272128B (hu)
WO (1)	WO1993000079A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5756094A (en) *	1991-03-27	1998-05-26	Trustees Of The University Of Pennsylvania	Methods for stimulating follicular growth
JPH10279501A (ja) *	1997-02-10	1998-10-20	Rohto Pharmaceut Co Ltd	育毛剤
US6087350A (en)	1997-08-29	2000-07-11	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US6136799A (en) *	1998-04-08	2000-10-24	Abbott Laboratories	Cosolvent formulations
FR2778558B1 (fr) *	1998-05-12	2001-02-16	Oreal	Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
AUPP489798A0 (en) *	1998-07-28	1998-08-20	Mediko Pty Ltd	Hair growth/maintenance compositions and methods
WO2002030430A1 (en) *	2000-10-06	2002-04-18	Abbott Laboratories	Use of vitamin d2 compounds for alopecia
US20030095937A1 (en) *	2001-10-02	2003-05-22	Koeffler H. Philip	Method for stimulating hair growth by administering vitamin D analogs
MX338746B (es)	2009-08-14	2016-04-29	Berg Llc	Vitamina d3 y analogos de la misma para tratar alopecia.
JP6370069B2 (ja) *	2014-03-17	2018-08-08	学校法人慶應義塾	まつ毛の成長を伸展するための組成物
WO2016056644A1 (ja) *	2014-10-09	2016-04-14	株式会社メディプロデュース	まつ毛用洗浄剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1275922C (en) *	1985-11-28	1990-11-06	Harunobu Amagase	Treatment of cancer
US5102870A (en) *	1989-04-14	1992-04-07	Schering Ag	Treatment and prevention of oral mucositis with growth factors

1992
- 1992-06-26 EP EP92914032A patent/EP0591378B1/en not_active Expired - Lifetime
- 1992-06-26 WO PCT/US1992/005241 patent/WO1993000079A1/en active IP Right Grant
- 1992-06-26 CZ CS932892A patent/CZ280874B6/cs unknown
- 1992-06-26 SK SK1490-93A patent/SK279673B6/sk unknown
- 1992-06-26 JP JP5501589A patent/JPH06509072A/ja active Pending
- 1992-06-26 DE DE69228814T patent/DE69228814T2/de not_active Expired - Fee Related
- 1992-06-26 HU HU9303753A patent/HUT66153A/hu unknown
- 1992-06-26 AT AT92914032T patent/ATE178206T1/de not_active IP Right Cessation
- 1992-06-26 AU AU22405/92A patent/AU667675B2/en not_active Ceased
- 1992-06-26 CA CA002112496A patent/CA2112496A1/en not_active Abandoned
- 1992-06-26 PT PT100638A patent/PT100638B/pt not_active IP Right Cessation
- 1992-06-28 IL IL102344A patent/IL102344A/en not_active IP Right Cessation
- 1992-06-29 PH PH44589A patent/PH31673A/en unknown
- 1992-07-01 IE IE208892A patent/IE922088A1/en not_active Application Discontinuation
- 1992-09-19 TW TW081107417A patent/TW272128B/zh active

Also Published As

Publication number	Publication date
EP0591378A1 (en)	1994-04-13
JPH06509072A (ja)	1994-10-13
TW272128B (hu)	1996-03-11
PT100638B (pt)	1999-09-30
WO1993000079A1 (en)	1993-01-07
IE922088A1 (en)	1992-12-30
PH31673A (en)	1999-01-18
CZ289293A3 (en)	1994-08-17
HUT66153A (en)	1994-09-28
SK149093A3 (en)	1994-08-10
DE69228814D1 (de)	1999-05-06
EP0591378B1 (en)	1999-03-31
CZ280874B6 (cs)	1996-04-17
PT100638A (pt)	1993-09-30
AU667675B2 (en)	1996-04-04
SK279673B6 (sk)	1999-02-11
CA2112496A1 (en)	1993-01-07
AU2240592A (en)	1993-01-25
EP0591378A4 (en)	1994-03-17
IL102344A0 (en)	1993-01-14
ATE178206T1 (de)	1999-04-15
IL102344A (en)	1998-01-04

Publication	Publication Date	Title
US6291443B1 (en)	2001-09-18	Method of preventing and treating chemotherapy-induced alopecia with vitamin D3 or a derivative or analog or active metabolite thereof.
DE4100975A1 (de)	1992-07-16	Kosmetische oder pharmazeutische zubereitungen zur verbesserung der haarqualitaet und foerderung des haarwachstums
DE3413052A1 (de)	1984-12-13	Pharmazeutische zubereitung und deren verwendung zur behandlung von hauterkrankungen
DE69027220T2 (de)	1997-01-02	Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
EP0209724B1 (de)	1991-09-25	Präparat mit Wirkung gegen Akne sowie Verwendung von Wirkstoffextrakt des Queckenweizens
DE69228814T2 (de)	1999-11-11	Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69326636T2 (de)	2000-04-06	Äusserliche Anwendung eines Kiefernextrakt enthaltenden, haarregenerierenden Mittels
DE3685696T2 (de)	1993-01-14	Melatoninhaltige mittel sowie deren verwendungen.
DE2740349A1 (de)	1978-03-09	Heilmittel zur linderung der symptome trockener haut
DE69524662T2 (de)	2002-08-08	Topisches Arzneimittel mit vernarbungsfördernder Wirkung
EP0765663A2 (de)	1997-04-02	Verwendung von Dienogest zur Herstellung eines Arzneimittels zur Behandlung der Haut mittels topischer Anwendung
WO2004039454A1 (de)	2004-05-13	Formulierungen enthaltend melatonin, ginkgo biloba und biotin
DE69525539T2 (de)	2002-09-26	Verwendung von 2,4-diaminopyrimidin-3-oxyd und/oder seine salze zur behandlungvon störungen der kollagenreifung oder -strukturierung
CH695983A5 (de)	2006-11-15	Tetraiodthyropropionsäure oder Tetraiodthyroessigsäure zur Herstellung eines dermatologischen Präparates.
DE3011437A1 (de)	1981-10-01	Pharmazeutisches mittel zur heilung von entzuendlichen und/oder degenerativen und/oder atrophischen schleimhauterkrankungen
DE69330429T2 (de)	2002-05-16	Verfahren zur behandlung von haarausfall
DE3615396A1 (de)	1987-11-12	Mittel zur behandlung der haare und der kopfhaut
WO1992000720A1 (de)	1992-01-23	Mittel und verfahren zur stimulierung des wachstums und der regenerierung des haares und der nägel
DE2401450A1 (de)	1974-07-18	Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
DE2117762A1 (de)	1972-05-10	Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung
EP1131101B1 (de)	2004-01-07	Khellin-zubereitung und deren verwendung zur topischen therapie
DE2757024C3 (de)	1981-01-22	Kosmetisches Haar- und Hautpflegemittel
DE1922192C2 (de)	1983-04-21	Zusammensetzungen zur Behandlung von trophischen Störungen der Haut und Verfahren zu ihrer Herstellung
DE602004005603T2 (de)	2008-01-24	Orale zusammensetzungen zur behandlung von cellulitis
DE69900336T2 (de)	2002-06-27	Pentoxifyllin und antizytokin enthaltende pharmazeutische zusammensetzungen

Legal Events

Date	Code	Title	Description
2000-04-27	8364	No opposition during term of opposition
2002-03-21	8328	Change in the person/name/address of the agent	Free format text: DERZEIT KEIN VERTRETER BESTELLT
2002-09-26	8339	Ceased/non-payment of the annual fee